Mere months after Pfizer's high profile exit from the inhaled
insulin market in the wake of Exubera's much publicised market
failure, Novo Nordisk announced late last night that it, too, has
decided to halt development of...
Pfizer may have given up on its non-injectable insulin, but
researchers in the US think they may have cracked a way to deliver
the hormone orally, linking it up to vitamin B12 to protect it
through the digestive system.
Eli Lilly is remaining optimistic about its yet-to-be-approved
inhaled insulin despite the dramatic downfall of Pfizer's Exubera.
But is Exubera's fall from grace an indication of things to come
for inhaled diabetes treatments?
Danish diabetes care specialist Novo Nordisk has expanded an
agreement with biotech supplier Millipore, granting exclusive,
long-term distribution rights to the company's insulin
products for cell culture applications.
An improved inhalable insulin product developed by collaborating UK
and US firms has just completed a glucose clamp study in the US,
with results suggesting that the product could pose a significant
threat to Pfizer's Exubera...
Bespak, one of the two contract manufacturers of Pfizer's inhaled
insulin Exubera, has announced it will cut a "significant" number
of jobs as sales of the once-touted blockbuster are falling short
Canadian biotech firm SemBioSys Genetics has presented an
update on its project to promote plant-derived recombinant human
insulin on a commercial scale, expecting to hop directly to Phase
II trials early next year.